Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
1.070
-0.010 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
30
31
Next >
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
February 03, 2022
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 03, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 02, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 02, 2022
Via
Investor Brand Network
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
February 02, 2022
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the...
Via
Benzinga
Lexaria (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Tech on EDGE Podcast
February 01, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast
January 31, 2022
Via
Investor Brand Network
Lexaria (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study
January 27, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
Investor Brand Network
Lexaria Provides Annual Letter From the CEO
January 27, 2022
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
January 21, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs
January 21, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
CannabisNewsWire
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
Via
Investor Brand Network
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
Investor Brand Network
After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
January 14, 2022
Via
Investor Brand Network
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing...
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.